ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts
ZN-c3 in combination with chemotherapy was well-tolerated, exhibiting a better hematologic and gastrointestinal tolerability profile within the Wee1 inhibitor class
Mini symposium on the ZN-c3 uterine serous carcinoma (USC) expansion cohort to be presented on April 11, 2022 at 2:50 p.m. CT
Updates on clinical and preclinical studies with ZN-c5 and ZN-d5
Company to host webcast event with key opinion leader, Kathleen Moore, MD, today, Friday, April 8 at 4:00 p.m. EDT
“Utilizing a continuous dosing regimen in patients with advanced disease, ZN-c3 demonstrated an Objective Response Rate of 30.2% across all cohorts – achieving up to 62.5% with one cohort – and a markedly better tolerability profile within the Wee1 inhibitor class. Based on these promising initial results, we believe the data support the development of a Phase 3 trial to further investigate this combination’s effect in ovarian cancer patients. We look forward to announcing our future development plans for this program before year-end and are motivated by the opportunity to potentially deliver an improved and best-in-class treatment option to patients.”
Summary of Clinical Activity
Cohort | N | Evaluable* (n) | PR/uPR+ (n) | SD/SD+ (n) | PD (n) | DCR (%) | ORR (%) |
Total | 56 | 43 | 13 | 24 | 6 | 86.0 | 30.2 |
ZN-c3 + PLD | 30 | 24 | 3 | 17 | 4 | 83.3 | 12.5 |
ZN-c3 + carboplatin | 17 | 11 | 5 | 4 | 2 | 81.8 | 45.5 |
ZN-c3 + paclitaxel | 9 | 8 | 5 | 3 | - | 100 | 62.5 |
Webcast Event:
Zentalis will host a webcast event with key opinion leader, Kathleen Moore, MD, today, Friday, April 8, 2022 at 4:00 p.m. EDT. Dr. Moore is the Associate Professor in the Section of Gynecologic Oncology; the Jim and Christy Everest Endowed Chair in Cancer Research; and the Director of the Oklahoma TSET Phase I Program for the Stephenson Cancer Center at the University of Oklahoma College of Medicine. She has a clinical research interest in drug development and Phase I trials and is a leading expert in gynecological oncology.
To register and access the event, the webcast link is available on the Investors & Media section of the Zentalis website at www.zentalis.com.
https://finance.yahoo.com/news/zentalis-pharmaceuticals-announces-positive-initial-170000516.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.